Xoma | XOMA - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Agenus USD -221.22M 241.03M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Ardelyx USD 127.27M 7.15M 2026-03
aTyr Pharma USD 2.42M 83.19M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Celldex Therapeutics USD 456.23M 368.95M 2026-03
Curis USD 9.02M 23.01M 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Incyte USD 5.62B 4.5B 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
Novartis USD 9.29B 507M 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Prothena USD 25.29M 1.94M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Xoma USD 22.84M 1.67M 2024-09